A randomized, double-blind, placebo-controlled trial of 22 patients with familial adenomatous polyposis (FAP) was conducted to evaluate the effect of sulindac on the number and size of colorectal adenomas. Patients received sulindac (150 mg twice daily) or placebo for nine months. The number and size of polyps were assessed every three months for one year. The results showed a statistically significant decrease in the mean number and diameter of polyps in the sulindac group compared to the placebo group. At nine months, the number of polyps had decreased to 44% of baseline values, and the size to 35% of baseline values. However, three months after stopping treatment, the number and size of polyps had increased slightly in the sulindac group, though they remained significantly lower than baseline. No significant adverse effects were observed. The study concluded that sulindac reduces the number and size of colorectal adenomas in patients with FAP, but its effect is incomplete and it is unlikely to replace colectomy as primary therapy. The findings suggest that sulindac may be a useful adjunct to colectomy in the management of FAP, but further studies are needed to evaluate its long-term efficacy and safety.A randomized, double-blind, placebo-controlled trial of 22 patients with familial adenomatous polyposis (FAP) was conducted to evaluate the effect of sulindac on the number and size of colorectal adenomas. Patients received sulindac (150 mg twice daily) or placebo for nine months. The number and size of polyps were assessed every three months for one year. The results showed a statistically significant decrease in the mean number and diameter of polyps in the sulindac group compared to the placebo group. At nine months, the number of polyps had decreased to 44% of baseline values, and the size to 35% of baseline values. However, three months after stopping treatment, the number and size of polyps had increased slightly in the sulindac group, though they remained significantly lower than baseline. No significant adverse effects were observed. The study concluded that sulindac reduces the number and size of colorectal adenomas in patients with FAP, but its effect is incomplete and it is unlikely to replace colectomy as primary therapy. The findings suggest that sulindac may be a useful adjunct to colectomy in the management of FAP, but further studies are needed to evaluate its long-term efficacy and safety.